BTIG将Enovis升级为2026年1月8日“强购”, BTIG upgraded Enovis to "strong-buy" Jan. 8, 2026, despite negative margins, citing insider buying and high analyst price targets.

Enovis(ENOV)于2026年1月8日由BTIG研究提升为“强购”, Enovis (ENOV) was upgraded to "strong-buy" by BTIG Research on January 8, 2026, amid mixed financials: the medical tech firm posted $0.59 EPS and $383.81M revenue in Q4, though it reported a negative net margin of 61.22%. 股票开放额为27.73美元,市场上限为1.59B美元,分析员的平均目标是46.71美元。 The stock opened at $27.73 with a market cap of $1.59B, and analysts’ average target is $46.71. 内幕John Kleckner在11月将股份增加了25%。 Insider John Kleckner increased his stake by 25% in November. 同时,Enova(ENVA)赚取了3.36美元的EPS(殴打估计数),收入增长了16.3%,股本回报率为24.5%。 Meanwhile, Enova (ENVA) earned $3.36 EPS, beating estimates, with a 16.3% revenue rise and a 24.5% return on equity. 其股票交易额为163.21美元,平均价格目标为136.50美元,并形成强有力的购买共识。 Its stock traded at $163.21, with a $136.50 average price target and a strong buy consensus.